Utility of Ovarian Tumour Marker Cancer Antigen-125 and Endocrine Hormonal Status in Polycystic Ovary Syndrome BC01-BC03
Dr. Vilas Namdeorao Kurude,
Flat No-20, 4th Floor, Trimurti Building-04, Sir JJ Hospital Campus, Byculla, Mumbai-400008, Maharashtra, India.
Introduction: Polycystic Ovary Syndrome (PCOS) is the most common endocrinopathy in women of reproductive age. Women with PCOS are at increased risk of reproductive abnormalities with a prevalence of up to 10%.
Aim: To assess the concentrations of ovarian tumour marker Cancer Antigen-125 (CA125), Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH) And Prolactin (PRL) among women with PCOS in order to get insight of how these biochemical parameters play a crucial role in the pathogenesis of PCOS and to evaluate their diagnostic utility.
Materials and Methods: A total of 60 subjects were enrolled for the prospective comparative case-control study. Out of these 60 subjects, a healthy control group of 30 subjects with non-hirsute, non-obese women with regular menstrual cycles were included as control. PCOS group of 30 women were selected as a study group who were already diagnosed by clinician. Their height (meters) and weight (kg) were measured and recorded. This measurement was used for calculating Body Mass Index (BMI) in kg/m2. Serum CA-125, LH, FSH and PRL were estimated by the chemiluminescent method on Immulite 1000. Data were presented as number, percentage, mean and standard deviation. Statistical analysis was done by normal distribution z-test.
Results: The statistical significant alterations were observed in the levels of CA125, LH and PRL between PCOS group and control group. FSH level was insignificantly different in PCOS as compared with that of controls.
Conclusion: An ovarian tumour marker CA125 and endocrine hormones such as LH, FSH and PRL are of paramount importance for the correct diagnosis with degree of severity in patients with PCOS. The present study confirms the elevated levels of LH as a regular feature of PCOS. Also, the possible correlation of CA125 and PRL in women having PCOS suggests that the combination of the ovarian tumour marker and this hormonal status can be used in biochemical screening of ovarian cancer. However, further prospective and controlled studies are needed to investigate their utility in prediction of ovarian cancer in women having PCOS.